PALO ALTO, Calif., March 9 /PRNewswire/ -- Frost & Sullivan's recent analysis of the Oxygen Therapy Devices Market selected CHAD Therapeutics, Inc. as the recipient of the 2006 Product Line Strategy Leadership Award for its excellence in the U.S. oxygen therapy devices market.
CHAD Therapeutics is a leading manufacturer of oxygen therapy products. Through its excellence in oxygen therapy, CHAD Therapeutics has recognized the shift toward market consolidation. As a result, the company has rapidly developed several new complementary products to expand its existing product portfolio.
"CHAD Therapeutics' competitive advantage lies in its continued innovation and expansive oxygen therapy product line," says Frost & Sullivan research analyst Sheila Ewing. "The company recognized the importance of efficient oxygen therapy devices, thus incorporating those improvements throughout the development of its devices."
With a vision far ahead of its time, CHAD Therapeutics began with the first oxygen conserver, the OXYMIZER Disposable Oxygen-Conserving Device in 1983. In 1986, the company introduced the first electronic conserver, the OXYMATIC Model 101. Their drive for continuous excellence led the company to develop cost-effective and efficient products such as the OXYMATIC 400 Series Electronic conservers, the SEQUOIA and CYPRESS OXYPneumatic conservers.
In 1997, CHAD Therapeutics created the TOTAL O2 Delivery System, allowing patients to fill cylinders at home. In 2004, the company added the SAGE Oxygen Therapeutic Device that utilizes dynamic sensor technology to automatically adjust to patients' needs.
CHAD Therapeutics' most recent development is the LOTUS electronic oxygen conserver. The company's expansion of its oxygen therapy devices and new marketing initiatives are major contributors to the company's success.
The company created its growth through strategic partnerships and significant investment in product development to rapidly prepare for intensified competition in the oxygen therapy industry. Behind this expansion of its product portfolio, CHAD Therapeutics recognized the threat of market consolidation and the emergence of new participants.
"To counter the threat of new participants and their recent products, CHAD Therapeutics positioned its products to address patients' needs with a broad range of oxygen therapy devices," notes Ewing. "Beyond the ability to provide products across the various needs of oxygen patients, CHAD Therapeutics maintains its commitment to provide the leading oxygen therapy technologies in all of its products."
In this competitive market, CHAD Therapeutics' survival and growth is a result of continuing efforts of its pioneering attitude. Competition, price pressure, and smaller profit margins are pushing market leaders to rapidly develop products to match end-user demand. By creating diversification and expansion in its oxygen therapy product line, CHAD Therapeutics continues to excel and maintain its leadership while increasing its market share. The company's enhanced value proposition will facilitate its future growth and create new opportunities for continued advancement.
Based on the company's product line and continued strategic innovation, Frost & Sullivan is proud to present CHAD Therapeutics, Inc. with the 2006 Oxygen Therapy Product Line Strategy Leadership Award.
Each year Frost & Sullivan presents this Award to a company that has demonstrated the most insight into customer needs and product demands. The recipient company has optimized its product line by leveraging products with the various price, performance and feature points required by the market.
About CHAD Therapeutics, Inc.
CHAD Therapeutics, Inc. is in the business of developing, producing and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. For more information visit, http://www.CHADtherapeutics.com .
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .
Contact: Stacie Jones 210.247.2450 Stacie.jones@frost.com
Frost & SullivanCONTACT: Stacie Jones of Frost & Sullivan, +1-210-247-2450, orStacie.jones@frost.com
